Slow Capital’s Atara Biotherapeutics ATRA Stock Holding History

Slow Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-36	Closed	-$12K	–	183
2020 Q3	$12K	Buy	+36	New	+$12.3K	﹤0.01%	218

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Slow Capital's ATRA Position: Q4 2020 in Review

Slow Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 36 shares — an estimated $12K sold.

Slow Capital first reported a position in ATRA in Q3 2020 and held it in 1 quarter. The position peaked at $12K in Q3 2020. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

Slow Capital reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
Slow Capital sold 36 Atara Biotherapeutics shares in Q4 2020, an estimated $12K.
Slow Capital first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 1 quarter.
Slow Capital's Atara Biotherapeutics position peaked at $12K in Q3 2020.
148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Slow Capital's 13F filing for Q4 2020, filed 11 Feb 2021.